The Role of IFITM Proteins in Tick-Borne Encephalitis Virus Infection

Alicja M Chmielewska1, Maria Gómez-Herranz2,3, Paulina Gach1

  • 1Laboratory of Virus Molecular Biology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdańskgrid.8585.0, Gdansk, Poland.

Journal of Virology
|October 6, 2021
PubMed

Insights

Interferon-induced transmembrane proteins (IFITMs) restrict tick-borne encephalitis virus (TBEV) infection and cell death. TBEV may escape IFITM immunity through cell-to-cell spread.

Area of Science:

  • Virology
  • Immunology
  • Cell Biology

Background:

  • Tick-borne encephalitis virus (TBEV) causes severe encephalitis in endemic regions.
  • Interferon-induced transmembrane proteins (IFITMs) are known to restrict flavivirus infections.
  • The role of IFITMs in TBEV infection has not been previously studied.

Purpose of the Study:

  • To investigate the role of IFITM1, IFITM2, and IFITM3 in restricting TBEV infection.
  • To determine the contribution of IFITMs to protection against TBEV-induced cell death.
  • To explore potential TBEV escape mechanisms from IFITM-mediated immunity.

Main Methods:

  • Utilized mutagenesis to dissect functional motifs of IFITM3.
  • Employed CRISPR-Cas9 technology to generate IFITM1/3-knockout cell lines.
  • Conducted coculture assays to assess TBEV cell-to-cell spread.

Main Results:

  • IFITM1, IFITM2, and IFITM3 significantly inhibit TBEV infection and TBEV-induced cell death.
  • IFITM3 plays the most critical role in antiviral defense against TBEV.
  • Endogenous IFITMs exhibit additive effects in suppressing TBEV replication.
  • TBEV demonstrates partial escape from IFITM-mediated suppression via cell-to-cell transmission.

Conclusions:

  • IFITM proteins are crucial innate immune factors against TBEV infection.
  • IFITM3 is a key effector in controlling TBEV.
  • TBEV cell-to-cell spread represents a potential mechanism to evade IFITM-mediated antiviral responses.
  • Understanding these interactions is vital for developing new antiviral strategies against TBEV.